H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on Arvinas Holding Company (NASDAQ:ARVN) on Friday, setting a price target of $135, which is approximately 87.14% above the present share price of $72.14.
Fein expects Arvinas Holding Company to post earnings per share (EPS) of -$0.94 for the fourth quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Arvinas Holding Company, with an average price target of $128.4.
The analysts price targets range from a high of $157 to a low of $115.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $9.28 million and a net profit of -$47.33 million. The company's market cap is $3.81 billion.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 7.7% and a 40.45% success rate.
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110 and ARV-471. The company was founded in February 2013 and is headquartered in New Haven, CT.